AERI Aerie Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AERI

Price (delayed)

$10.66

Market cap

$526.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.04

Enterprise value

$824.03M

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. ...

Highlights
The gross profit has surged by 160% year-on-year and by 4.9% since the previous quarter
The company's revenue has surged by 118% YoY and by 3% QoQ
Aerie Pharmaceuticals's debt has increased by 43% YoY
AERI's equity is down by 12% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.aeriepharma.com
Peers: INSM LXRX ALIM MRK

Key stats

What are the main financial stats of AERI
Market
Shares outstanding
49.36M
Market cap
$526.18M
Enterprise value
$824.03M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.98
Earnings
Revenue
$207.13M
EBIT
-$48.14M
EBITDA
-$21.71M
Free cash flow
-$5.16M
Per share
EPS
-$1.04
Free cash flow per share
-$0.11
Book value per share
-$2.9
Revenue per share
$4.35
TBVPS
$8.1
Balance sheet
Total assets
$385.34M
Total liabilities
$526.47M
Debt
$337.29M
Equity
-$141.13M
Working capital
$191.75M
Liquidity
Debt to equity
-2.39
Current ratio
2.6
Quick ratio
2.11
Net debt/EBITDA
-13.72
Margins
EBITDA margin
-10.5%
Gross margin
88.2%
Net margin
-23.9%
Operating margin
-15.6%
Efficiency
Return on assets
-12.6%
Return on equity
N/A
Return on invested capital
-9.3%
Return on capital employed
-18.1%
Return on sales
-23.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AERI stock price

How has the Aerie Pharmaceuticals stock price performed over time
Intraday
19.64%
1 week
67.35%
1 month
25.41%
1 year
-29.96%
YTD
51.85%
QTD
42.13%

Financial performance

How have Aerie Pharmaceuticals's revenue and profit performed over time
Revenue
$207.13M
Gross profit
$182.64M
Operating income
-$32.41M
Net income
-$49.42M
Gross margin
88.2%
Net margin
-23.9%
The gross profit has surged by 160% year-on-year and by 4.9% since the previous quarter
The company's revenue has surged by 118% YoY and by 3% QoQ
The operating margin has soared by 89% YoY and by 32% from the previous quarter
Aerie Pharmaceuticals's net margin has soared by 86% YoY and by 30% from the previous quarter

Growth

What is Aerie Pharmaceuticals's growth rate over time

Valuation

What is Aerie Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.98
AERI's EPS has soared by 71% YoY and by 29% from the previous quarter
AERI's equity is down by 12% since the previous quarter
The company's revenue has surged by 118% YoY and by 3% QoQ
The price to sales (P/S) is 97% less than the 5-year quarterly average of 94.6 and 9% less than the last 4 quarters average of 2.7

Efficiency

How efficient is Aerie Pharmaceuticals business performance
AERI's ROS has soared by 86% YoY and by 31% from the previous quarter
The ROIC has soared by 78% YoY and by 34% from the previous quarter
The ROA has soared by 72% YoY and by 30% from the previous quarter

Dividends

What is AERI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AERI.

Financial health

How did Aerie Pharmaceuticals financials performed over time
Aerie Pharmaceuticals's total assets is 27% lower than its total liabilities
The total liabilities has grown by 33% YoY
Aerie Pharmaceuticals's total assets has increased by 8% YoY but it has decreased by 2.6% QoQ
AERI's debt to equity has surged by 60% year-on-year and by 11% since the previous quarter
Aerie Pharmaceuticals's debt has increased by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.